Palisade Bio

Name: Palisade Bio
Address: 5800 Armada Drive, Suite 210, Carlsbad, CA, 92008, US
Telephone: +18587044900

Call Directions Website Contact the business

Palisade Bio (Nasdaq: PALI) is advancing next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases.

10/28/2026

Palisade Bio President & Chief Medical Officer Dr. Mitch Jones highlights the design and objectives of the Company's ASCENTRA-UC Phase 2 clinical study evaluating PALI-2108 for ulcerative colitis.

Building on encouraging Phase 1 findings, the study is designed to evaluate the efficacy and safety of PALI-2108 across two once-daily oral dose levels, with clinical remission at Week 12 serving as the primary endpoint.

With clinical site activation ahead of schedule and substantially all U.S. sites now activated, Palisade Bio continues to advance the clinical development of PALI-2108.

10/28/2026

Palisade Bio CEO JD Finley highlights the significance of dosing the first patient in the Company's ASCENTRA-UC Phase 2 clinical study evaluating PALI-2108 for ulcerative colitis.

This milestone represents an important step in advancing PALI-2108 as a potential once-daily oral treatment for patients with ulcerative colitis. With U.S. enrollment underway and global expansion progressing, the Company looks forward to reporting topline induction results in the fourth quarter of 2027.

10/28/2026

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis

https://bit.ly/4dXWZfC

10/20/2026

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

https://bit.ly/480y5Zc

10/12/2026

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

https://bit.ly/4dAswUE

09/28/2026

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

https://bit.ly/3TszDaQ

09/23/2026

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

https://bit.ly/4AsKL83

09/22/2026

Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

https://bit.ly/4xEMEMm

09/21/2026

Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

https://bit.ly/4rrrboP

09/11/2026

Palisade Bio’s J.D. Finley and Mitchell L. Jones joined The BioHub by Avetix for a conversation on the progress of PALI-2108 and what lies ahead as we advance toward our Phase 2 ASCENTRA-UC study.

Listen to the full episode: https://bit.ly/4h5DgfJ

Address

5800 Armada Drive, Suite 210
Carlsbad, CA
92008

Telephone

+18587044900

Website

https://www.palisadebio.com/

Alerts

Be the first to know and let us send you an email when Palisade Bio posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.